PHARMAC’s decision not to fund melanoma treatment pembrolizumab – marketed as Keytruda – has been widely covered in the media. Public […]
Continue readingPHARMAC’s decision not to fund melanoma treatment pembrolizumab – marketed as Keytruda – has been widely covered in the media. Public […]
Continue reading